I had said the the 5% not successful vs. 95% successful in the trial consisted of an imbalance between the leronlimab arm and placebo/SOC.

Quote:

---

1) A higher proportion of patients over 65 were enrolled in the leronlimab arm (33%) compared to the placebo arm (23%), and
(2) Of the 384 treated patients, 117 were over 65 with an overall mortality rate 3.5 times higher (42% - 49/117) than for patients under 65 (12% - 31/267).

---